Cargando…
Pembrolizumab Plus Chemotherapy in Metastatic Thymic Carcinoma: A Case Report
Metastatic thymic carcinomas have a poor prognosis. Pembrolizumab, an anti-PD-1 antibody, has recently been evaluated for patients with metastatic thymic carcinomas progressing after at least one line of platinum-based chemotherapy. The antitumor activity of immunotherapy appears to be promising for...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8810527/ https://www.ncbi.nlm.nih.gov/pubmed/35127529 http://dx.doi.org/10.3389/fonc.2021.814544 |